Brands of Cefpirome in Kenya:
Forgen®, Alkem
Cefpirome is a fourth-generation cephalosporin antibiotic.
Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria.
Cefpirome Mechanism of Action:
Cefpirome binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
INDICATIONS
Cefpirome is primarily indicated in conditions like Bacteremia, Lower respiratory tract infections, Pneumonia, Promyelocytic leukemia, Septicaemia, Severe infections including bacteraemia and septicaemia and infections in neutropenic patients, Skin infections, Soft tissue infections, Urinary tract infection.
DOSAGE AND ADMINISTRATION
1-4 g IV every 12 Hours
Inject over 3-5 min , OR
Intermittent infussion over 20-30 min
DRUG INTERACTIONS
- Cefpirome decreases effects of BCG vaccine live by pharmacodynamic antagonism.
- Cefpirome will decrease the level or effect of bazedoxifene / conjugateds estrogens by altering intestinal flora.
- Cefpirome will increase level of digoxin by altering intestinal flora.
- Flucloxacillin: Either increases levels of each other by decreasing renal clearance.
- Cefpirome will increase levels of probenecid by acidic (anionic) drug competition for renal tubular clearance
ADVERSE REACTIONS
Skin: Rash, itching and hives.
Gastrointestinal: Nausea, vomiting, abdominal pain and diarrhea.
Liver: Increased level of liver enzymes.
Genitourinary: Kidney inflammation/impairment.
Blood: Decrease in blood counts.
Local: Pain and swelling.
Miscellaneous: Fever and epilepsy.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Cefpirome in Kenya
Cefpirome in Kenya
Cefpirome in Kenya
Cefpirome in Kenya
Cefpirome in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: injection
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: N/A
Elimination Half life: Not Available
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
| CAS Number | |
|---|---|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
Drug Images
References/ Citation:
- PPB Drugs Retention Register
- Wiseman, Lynda R., and Harriet M. Lamb. “Cefpirome.” Drugs 54.1 (1997): 117-140.